Remifentanil Requirement in Patients Receiving Surgical Treatment of Parkinson's Disease

NCT01992692 | Completed DMC

• 1 other identifier: Parkinson-remifentanil
• Study Type: observational
• Target: 62
• Locations: 1 country
• Sites: 1

Brief Summary

Parkinson's disease (PD) is one the main neurodegenerative disease with an incidence of about 3% in patients older than 65 years. Anesthesia in PD patients has been focused by several studies for concerning the interactive reaction between anesthetics and anti-Parkinsonian medication or Parkinsonian symptoms. However, our previous experience showed that the patients undergoing pulse generator placement were more prone to be involved in delayed emergence in the recovery room, which had been not reported yet. We speculated that PD patients might be a special population with abnormal pharmacodynamic characters of anesthetics, though no related evidence could be found to support this hypothesis. Therefore, in this project we investigated whether remifentanl requirement to inhibit patients' response to trachea intubation and skin insertion in PD patients undergoing DBS and pulse generator placement was different from non-PD patients undergoing intracranial surgery for reasons other than PD.

Conditions

Parkinson's Disease

Keywords

Parkinson's disease; remifentanil; deep brain stimulator; cardiovascular response

Outcome Measures

Primary Outcomes (1)

• Concentrations required to inhibit response to trachea intubation and skin incision

  Anesthesia induction to 5min after skin incision

Study Arms (2)

PD group

Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement

non-PD group

Non-Parkinsonian patients undergoing intracranial surgery

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement, as well as non-Parkinsonian patients undergoing intracranial surgery

You may qualify if:

• Adult Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
• Adult non-Parkinsonian patients undergoing intracranial surgery

You may not qualify if:

• ASA score higher than Class II
• predicted difficult airway
• alcohol or drug abuser
• informed consent was not provided

Sponsors & Collaborators

• Changhai Hospital: lead

Study Sites (1)

Department of Anesthesiology, Changhai Hospital

Shanghai, Shanghai Municipality, 200433, China

Location

Related Publications (1)

• Wang JF, Xu XP, Yu XY, Li JB, Wu X, Chen JC, Hu XW, Deng XM. Remifentanil Requirement for Inhibiting Responses to Tracheal Intubation and Skin Incision Is Reduced in Patients With Parkinson's Disease Undergoing Deep Brain Stimulator Implantation. J Neurosurg Anesthesiol. 2016 Oct;28(4):303-8. doi: 10.1097/ANA.0000000000000229.

  PMID: 26368663 DERIVED

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: November 19, 2013
• First Posted: November 25, 2013
• Study Start: January 1, 2012
• Primary Completion: June 1, 2013
• Study Completion: June 1, 2013
• Last Updated: November 25, 2013

Record last verified: 2013-06

Locations

CN (1)